US Stem Cell (US Stem Cell) Cash, Cash Equivalents, Marketable Securities : $0.01 Mil (As of Dec. 2022)

View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Cash, Cash Equivalents, Marketable Securities?

US Stem Cell's quarterly cash, cash equivalents, marketable securities increased from Jun. 2022 ($0.01 Mil) to Sep. 2022 ($0.03 Mil) but then stayed the same from Sep. 2022 ($0.03 Mil) to Dec. 2022 ($0.01 Mil).

US Stem Cell's annual cash, cash equivalents, marketable securities increased from Dec. 2020 ($0.02 Mil) to Dec. 2021 ($0.04 Mil) but then declined from Dec. 2021 ($0.04 Mil) to Dec. 2022 ($0.01 Mil).

US Stem Cell Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for US Stem Cell's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Cash, Cash Equivalents, Marketable Securities Chart

US Stem Cell Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

1.36

0.02

0.04

0.01

US Stem Cell Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															0.04	0.01	0.01	0.03	0.01

US Stem Cell Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

US Stem Cell (OTCPK:USRM) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

US Stem Cell Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

US Stem Cell (US Stem Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323

Website

http://www.us-stemcell.com

US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

Executives

Murphy William P Jr	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson	director	14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman	director	5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart	director	19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson	director	1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella	officer: Chief Science Officer	1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee	director	54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth	director	1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich	officer: Vice President,Sales&Marketing	482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson	director	11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt	director, 10 percent owner, officer: Executive Chairman & CTO	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott	officer: VP of Public Relations	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325